PFDN4 and invasive breast carcinoma: The disease-specific prognostic value of PFDN4 (PFDN4 uses median to differentiate between high and low expression) with drug including doxorubicin (Figure 3A), paclitaxel (Figure 3B), cyclophosphamide (Figure 3C), tamoxifen (Figure 3D), anastrazole (Figure 3E) and docetaxel (Figure 3F) was determined using Kaplan–Meier analysis in breast invasive carcinoma.